Antitumor activity of dextran derivatives immobilizing platinum complex (II)

Anti-Cancer Drugs

Volumn 11, Issue 1, 2000, Pages 33-38

  Ichinose, Katsuro ^a,b   Tomiyama, Naoki ^b   Nakashima, Mikiro ^b   Ohya, Yuichi ^b,c   Ichikawa, Masataka ^b   Ouchi, Tasturo ^b,c   Kanematsu, Takashi ^b  

^a Departments of Surgery II   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANSAI UNIVERSITY   (Japan)

Author keywords

Antitumor activity; Cisplatin; Dextran; Drug delivery system; Polymeric drug

Indexed keywords

CISPLATIN DERIVATIVE; DEXTRAN DERIVATIVE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; COLON CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TISSUE LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXTRANS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PRODRUGS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034109240     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200001000-00006     Document Type: Article

References (15)

1. 1. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiamine platinum (II) in man. Cancer Treat Rep 1979; 63: 1522-31.
2. 2. Sezaki H, Hashida M, Muranishi S. Gelatine microspheres as carriers for antineoplastic agents. In: Bungaard H, Hansen AB, Kofod H, eds. Optimization of drug delivery. Copenhagen: Munksgaard 1982: 316-32.
3. 3. Hashida M, Takakura Y. Pharmacokinetics in design of polymeric drug deliver systems. J Controlled Rel 1994; 31: 163-71.
4. 4. Ohya Y, Nonomura K, Ouchi T. In vivo and in vitro anticancer activity of CM-chitin immobilized doxorubicins by lysosomal digestible tetrapeptide spacer groups. J Bioact Compat Polym 1995; 10: 223-34.
5. 5. Larsen C. Dextran prodrugs - structure and stability in relation to therapeutic activity. Adv Drug Del Rev 1989; 3: 25-35.
6. 6. Hashida M, Takakura Y, Matsumoto S, et al. Regeneration characteristics of Mitomycin C-dextran conjugate in relation to its activity. Chem Pharmac Bull 1983; 31: 2055-63.
7. 7. Ohya Y, Masunaga T, Baba T, et al. Synthesis and cytotoxic activity of dextran carrying cis-dichloro(cyclohexane-trans-l-1,2 diamine) platinum (II) complex. J Biomater Sci Polym Edn 1996; 7: 1085-96.
8. 8. Ohya Y, Masunaga T, Baba T, et al. Synthesis and cytotoxic activity of dextran-immobilizing platinum (II) complex through chelate-type coordination bond. J Macromol Sci Pure Appl Chem 1996; A33: 1005-16.
9. 9. Nakashima M, Ichinose K, Kanematsu T, et al. In vitro characteristics and in vivo disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextran. Biol Pharmac Bull 1999; 22: 756-61.
10. 10. Tokunaga Y, Nakashima M, Shibata S, et al. Antitumor effects of 4-pyridoxate diamine hydroxy platinum, a novel cisplatin derivative, against malignant gliomas in vitro and in vivo; a comparison with cisplatin. Pharmac Sci 1997; 3: 353-6.
11. 11. Schechter B, Pauzner R, Arnon R, et al. Cis-platinum (II) complexes of carboxymethyldextran as potential antitumor agents I. preparation and characterization. Cancer Biochem Biophys 1986; 8: 277-87.
12. 12. Safirstein R, Winston J, Moel D, et al. Cisplatin nephrotoxicity: insights into mechanism. Int J Androl 1987; 10: 325-46.
13. 13. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
14. 14. Takakura Y, Takagi A, Hashida M, et al. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharmac Res 1987; 4: 293-300.
15. 15. Levi-Schaffer A, Bernstein A, Meshorer A, et al. Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat Rep 1982; 66: 107-14.